Combination treatment with bevacizumab and 5-fluorouracil (5-FU) based chemotherapy improves overall survival and progression free survival of patients with metastatic colo-rectal cancer (mCRC). But, arterial thromboembolism (ATE) and venous thromboembolism (VTE) were associated with bevacizumab, VEGF inhibitor. This study was performed to determine the risk of ATE and VTE associated with the use of bevacizumab. Total of 410 patients with m CRC who were administered combination treatment with bevacizumab and chemotherapy versus chemotherapy alone from January 2007 to August 2010 in Asan Medical Center were enrolled.
Data was collected retrospectively from electronic medical record (EMR). The risk of thromboembolism (TE) was assessed by simple incidence rates and hazard ratios (HRs). The association between potential risk factors and TE was investigated by Cox proportional hazards regression.
Combination treatment with Bevacizumab and chemotherapy, compared with chemotherapy alone, increased incidence rate of TE (9.8% vs 3.7%, p=0.018), VTE (6.1% vs 2%, p=0.038) and ATE (4.4% vs 1.7%, p=0.109). Univariate and multivariate HR of Bevacizumab group were respectively 3.09 (p=0.009), 5.90 (p=0.016). In conclusion, The use of bevacizumab was significantly associated with the increased risk of developing TE in mCRC receiving this drug. Further studies are needed to investigate the prevention and management of TE associated with bevacizumab.
KCI 후보
전이성 대장암 환자에서 혈관신생억제제 Bevacizumab 치료로 인한 혈전색전증 위험
Risk of Thromboembolism with the Angiogenesis inhibitor Bevacizumab in Metastatic Colo-Rectal Cancer Patients
병원약사회지
약어 : JKSHP
2011 vol.28, no.3, pp.1 - 9
DOI : 10.32429/jkshp.2011.28.3.001
발행기관 : 한국병원약사회
연구분야 : 약학
Copyright © 한국병원약사회
약어 : JKSHP
2011 vol.28, no.3, pp.1 - 9
DOI : 10.32429/jkshp.2011.28.3.001
발행기관 : 한국병원약사회
연구분야 : 약학
Copyright © 한국병원약사회
bevacizumab, thromboembolism
- 1. [학술지] Giantonio B.J / 2007 / Bevacizumab in combination with oxaliplatin,fluorouracil, and leucovorin(FOLFOX4)for previously treated metastaticcolorectal cancer: results from theEastern Cooperative Oncology GroupStudy E3200 / J Clin Oncol / 25 (12) : 1539 ~ 12
- 2. [학술지] Hurwitz H.I. / 2005 / Bevacizumab in combination with fluorouraciland leucovorin: an active regimenfor first-line metastatic colorectal cancer / J Clin Oncol / 23 (15) : 3502 ~ 15
- 3. [학술지] Kbbinavar F / 2003 / Phase II, randomizedtrial comparing bevacizumab plusfluorouracil(FU)/leucovorin(LV) withFU/LV alone in patients with metastaticcolorectal cancer / J Clin Oncol / 21 (1) : 60 ~ 1
- 4. [학술지] Grothey A / 2008 / Bevacizumab beyond first progression isassociated with prolonged overall survivalin metastatic colorectal cancer: resultsfrom a large observational cohortstudy(BRiTE) / J Clin Oncol / 26 : 5326 ~
- 5. [학술지] Kozloff M / 2009 / Clinical outcomes associatedwith bevacizumab-containing treatmentof metastatic colorectal cancer: TheBRiTE observational Cohort Study / TheOncologist / 14 : 862 ~
- 6. [학술지] Nalluri S.R / 2008 / Risk of Venous Thromboembolismwith the Angiogenesis InhibitorBevacizumab in Cancer Patients / Jama / 300 (19) : 2277 ~ 19
- 7. [학술지] Gressett S.M / 2009 / Intricacies ofBevacizumab-induced toxicities andtheir management / The annals of Pharmacotherapy / 43
- 8. [학술지] Ranpura V / 2010 / Risk of cardiac ischemia and arterialthromboembolic events with the angiogenesisinhibitor bevacizumab in cancerpatients: A meta-analysis of randomizedcontrolled trials / Acta Oncologia / 49 : 287 ~
- 9. [학술지] Saif M.W. / 2006 / Incidence andmanagement of bevacizumab-relatedtoxicities in colorectal cancer, ExpertOpin / Drug Saf / 5 (4) : 553 ~ 4
- 10. [학술지] Shord S.S / 2009 / Understandingand managing the possible adverseeffects associated with bevacizumab / AmJ Health-Syst Pharm / 66 : 1
- 11. [학술지] Scappaticci F.A / 2007 / ArterialThromboembolic Events in Patients withMetastatic Carcinoma Treated withChemotherapy and Bevacizumab / J NatlCancer inst / 99 : 1232 ~
- 12. [학술지] Hurwitz H.I. / 2011 / Venous ThromboembolicEvents With Chemotherapy plusBevacizumab: A Pooled Analysis ofPatients in Randomized Phase II and IIIStudies / J Clin Oncol / 29 : 1757 ~
- 13. [단행본] / 2008 / Avastin(Bevacizumab) package insert / Genetech, Inc
- 14. [학술지] Sousou T / 2009 / New insightsInto Cancer-Associated Thrombosis / Arterioscler Thromb Vasc Biol / 29 : 316 ~
- 15. [학술지] Agnelli G / 2006 / AClinical outcome-based prospectivestudy on Venous thromboembolism aftercancer surgery / The @RISTOS project,Ann surg / 243 : 89 ~
- 16. [학술지] Lee A.Y / 2006 / Incidence, risk factors, and outcomes ofcatheter-related thrombosis in adultpatients with cancer / J Clin oncol / 24 : 1404 ~
- 17. [학술지] Khorana A.A. / 2008 / Development and validation of a predictive model forchemotherapy-associated thrombosis / Blood / 111 : 4902 ~
- 18. [학술지] Ay C / 2008 / High plasma levels of soluble p-selectinare predictive of venous thromboembolismin cancer patients: results fromthe Vienna Cancer and ThrombosisStudy(CATS) / Blood / 112 : 2703 ~
- 19. [학술지] Hurwitz H.I. / 2005 / Bevacizumab in Combination WithFluorouracil and leucovorin : An Activeregimen for First-Line MetastaticColorectal Cancer / J Clin Oncol / 23 (15) : 3502 ~ 15
타입을 선택하세요
전이성 대장암 환자에서 혈관신생억제제 Bevacizumab 치료로 인한 혈전색전증 위험
@article{ART001587538},
author={
신보람
and
이효정
and
박윤희
and
김재연
and
곽혜선
and
송영천
},
title={
전이성 대장암 환자에서 혈관신생억제제 Bevacizumab 치료로 인한 혈전색전증 위험
},
journal={
병원약사회지
},
issn={1226-640X},
year={2011},
number={3},
pages={1 - 9},
doi={10.32429/jkshp.2011.28.3.001},
url={http://dx.doi.org/10.32429/jkshp.2011.28.3.001}
TY - JOUR
AU - 신보람
AU - 이효정
AU - 박윤희
AU - 김재연
AU - 곽혜선
AU - 송영천
TI - 전이성 대장암 환자에서 혈관신생억제제 Bevacizumab 치료로 인한 혈전색전증 위험
T2 - 병원약사회지
PY - 2011
VL - 28
IS - 3
PB - 한국병원약사회
SP - 1 - 9
SN - 1226-640X
AB - Combination treatment with bevacizumab and 5-fluorouracil (5-FU) based chemotherapy improves overall survival and progression free survival of patients with metastatic colo-rectal cancer (mCRC). But, arterial thromboembolism (ATE) and venous thromboembolism (VTE) were associated with bevacizumab, VEGF inhibitor. This study was performed to determine the risk of ATE and VTE associated with the use of bevacizumab. Total of 410 patients with m CRC who were administered combination treatment with bevacizumab and chemotherapy versus chemotherapy alone from January 2007 to August 2010 in Asan Medical Center were enrolled.
Data was collected retrospectively from electronic medical record (EMR). The risk of thromboembolism (TE) was assessed by simple incidence rates and hazard ratios (HRs). The association between potential risk factors and TE was investigated by Cox proportional hazards regression.
Combination treatment with Bevacizumab and chemotherapy, compared with chemotherapy alone, increased incidence rate of TE (9.8% vs 3.7%, p=0.018), VTE (6.1% vs 2%, p=0.038) and ATE (4.4% vs 1.7%, p=0.109). Univariate and multivariate HR of Bevacizumab group were respectively 3.09 (p=0.009), 5.90 (p=0.016). In conclusion, The use of bevacizumab was significantly associated with the increased risk of developing TE in mCRC receiving this drug. Further studies are needed to investigate the prevention and management of TE associated with bevacizumab.
KW - bevacizumab, thromboembolism
DO - 10.32429/jkshp.2011.28.3.001
UR - http://dx.doi.org/10.32429/jkshp.2011.28.3.001
ER -
신보람 , 이효정 , 박윤희 , 김재연 , 곽혜선 and 송영천 (2011). 전이성 대장암 환자에서 혈관신생억제제 Bevacizumab 치료로 인한 혈전색전증 위험. 병원약사회지, 28(3), 1 - 9.
신보람 , 이효정 , 박윤희 , 김재연 , 곽혜선 and 송영천 . 2011, “전이성 대장암 환자에서 혈관신생억제제 Bevacizumab 치료로 인한 혈전색전증 위험”, vol.28, no.3, pp. 1 - 9. Available from: doi:10.32429/jkshp.2011.28.3.001
신보람 외. “전이성 대장암 환자에서 혈관신생억제제 Bevacizumab 치료로 인한 혈전색전증 위험“ 병원약사회지 28.3 pp. 1 - 9. (2011): 1.
신보람 , 이효정 , 박윤희 , 김재연 , 곽혜선 , 송영천 . 전이성 대장암 환자에서 혈관신생억제제 Bevacizumab 치료로 인한 혈전색전증 위험 병원약사회지 [Internet]. 2011; 28(3), : 1 - 9. Available from: doi:10.32429/jkshp.2011.28.3.001
신보람 , 이효정 , 박윤희 , 김재연 , 곽혜선 and 송영천 . “전이성 대장암 환자에서 혈관신생억제제 Bevacizumab 치료로 인한 혈전색전증 위험“ 병원약사회지 28, no.3, (2011): 1 - 9. doi: :10.32429/jkshp.2011.28.3.001